Thank you very much.
Thank you so much, Mr. Chair.
Let me begin by acknowledging that I am meeting with you from the territory of many first nations, including the Mississaugas of the Credit, the Anishinabe, the Chippewa, the Haudenosaunee and the Wendat peoples.
With me today I have Deputy Minister Bill Matthews and others from our team.
I am very pleased to be here to contribute to this committee's study on the government's response to the COVID-19 pandemic.
Since the first days of the pandemic, my department has worked around the clock to procure essential personal protective equipment and other medical supplies to protect our frontline health care workers.
Given the rapidly evolving and uncertain nature of the pandemic, we proactively procured a vast range of equipment and supplies so that Canada would be prepared for any eventuality, including worst-case scenarios.
We fought hard in a hypercompetitive global market to secure urgently needed equipment and supplies. We have procured in total about 2.7 billion items of PPE across a range of supplies, and 1.5 billion of those items have been delivered to date.
At the same time, Canadian companies across this land answered our call and began to ramp up domestic production. Last year at this time, N95 masks were not produced in this country. Now Medicom in Quebec is producing N95s. It has produced 100 million masks to date. Medicom in Quebec is joined by 3M in Brockville, which has produced one million N95s to date.
Forty per cent of our PPE contracts, by dollar value, are with Canadian companies. Having these diverse supply chains operating simultaneously was one of the key items in our strategy relating to the procurement of PPE.
Despite the very best efforts of so many Canadians to follow public health advice and make so many personal sacrifices, we are in the midst of the third wave of this pandemic. Our PPE procurements prepared our supply accordingly, and we will continue to support the Public Health Agency of Canada and the provinces and territories as we make our way through to the other side of this pandemic.
We know that the only way to conquer COVID-19 is for us all to continue to follow public health advice alongside a successful vaccine rollout.
When securing doses of safe and effective vaccines for Canadians we took the same aggressive approach as in our personal protective equipment procurement. We initiated a science-based strategy to secure as many vaccine doses as possible.
We approached manufacturers early, negotiating aggressively to build a portfolio of the most promising vaccines to protect the health of Canadians. My department also procured supplies, such as 175 million needles and 262 million syringes to administer the vaccines, as well as hundreds of freezers for use across this country.
Mr. Chair, we laid the groundwork for the largest inoculation campaign in this country's history, and our portfolio of vaccine candidates is now delivering for Canadians.
We originally were promised six million doses of vaccines before the end of Q1. We exceeded this target by 3.5 million doses and reached 9.5 million doses by the end of Q1. That is an excess of 3.5 million doses for which my department and I negotiated aggressively.
Now Canada is in the top three G20 countries in terms of the rate of people who have received at least one dose of vaccine and in the top four for total vaccines administered to date by population. Twelve million doses of the Health Canada-approved Pfizer, Moderna and AstraZeneca vaccines have been delivered to provinces and territories as of today, with 8.8 million vaccines administered to date.
Every day more and more Canadians are rolling up their sleeves and getting their shot. At the same time, my department and I continue to negotiate for earlier and earlier deliveries from vaccine suppliers. We have been successful in doing so. To be very clear, it is my role to get these vaccines to Canada as quickly as possible, and that's exactly what I'm doing.
Our most recent efforts are bearing significant results. Between April and June, we will now be receiving 18 million doses of the Pfizer vaccine rather than the originally scheduled eight million doses. Altogether, we have accelerated 22 million doses to earlier quarters—22 million doses earlier than what was otherwise targeted.
In addition, Moderna has confirmed that in addition to the shipment we received this week, we should expect just over 1.2 million doses to arrive at the end of April and more than 2.8 million doses in May. We have also negotiated for millions of AstraZeneca doses to arrive, and they will be continuing to come into this country.
As a result of the successful negotiations, Mr. Chair, by the end of September or before, we will have more than enough doses for every eligible person in Canada.
In closing, the Government of Canada continues to provide information about the number of doses coming into the country. We have exceeded our targets, but we are far from finished.
While supply chains are stronger, vaccines are moving directly from production to shipping so any manufacturing issues have a direct impact on delivery timelines.
To help mitigate these potential schedule disruptions, we are working very closely with suppliers and, through the Public Health Agency, with provinces and territories so that information is shared in real time.
As I mentioned, I am personally pushing our suppliers every day for even earlier delivery of vaccines.
Mr. Chair, our government will keep doing whatever it takes to get Canadians through to the other side of the pandemic. At PSPC, we will support this effort through our procurements.
I look forward to taking your questions.
Thank you.